Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevaciz
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04:00pm, Thursday, 28'th May 2026
ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizu
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA
09:16am, Tuesday, 26'th May 2026
Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration granted its appeal following the Formal Dispute Resolu
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
07:00am, Tuesday, 26'th May 2026
ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizu
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
06:25pm, Friday, 15'th May 2026
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.4 per share a year ago.
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
04:05pm, Friday, 15'th May 2026
ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ret
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
04:05pm, Thursday, 23'rd Apr 2026
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the stand
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:30am, Wednesday, 22'nd Apr 2026
ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the stand
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
09:05am, Tuesday, 21'st Apr 2026
ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
08:50am, Tuesday, 07'th Apr 2026
ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
04:05pm, Wednesday, 25'th Mar 2026
ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
07:00am, Tuesday, 24'th Mar 2026
ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Announces Proposed Public Offering
05:30pm, Monday, 23'rd Mar 2026
ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
08:05am, Monday, 16'th Mar 2026
ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
08:19am, Wednesday, 11'th Mar 2026
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
